Literature DB >> 17189529

What is this thing called CFA?

A U Wells, D M Hansell, A G Nicholson.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17189529      PMCID： PMC2111276          DOI： 10.1136/thx.2005.051011

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  12 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP.

Authors:  S Nagai; M Kitaichi; H Itoh; K Nishimura; T Izumi; T V Colby
Journal:  Eur Respir J       Date:  1998-11       Impact factor: 16.671

3.  British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.

Authors:  I D Johnston; R J Prescott; J C Chalmers; R M Rudd
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

4.  British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival.

Authors:  Robin M Rudd; Robin J Prescott; J C Chalmers; Ian D A Johnston
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

5.  Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis.

Authors:  Moises Selman; Annie Pardo; Lourdes Barrera; Andrea Estrada; Susan R Watson; Keith Wilson; Natasha Aziz; Naftali Kaminski; Albert Zlotnik
Journal:  Am J Respir Crit Care Med       Date:  2005-09-15       Impact factor: 21.405

6.  The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

Authors:  A G Nicholson; T V Colby; R M du Bois; D M Hansell; A U Wells
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

7.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

8.  Radiological versus histological diagnosis in UIP and NSIP: survival implications.

Authors:  K R Flaherty; E L Thwaite; E A Kazerooni; B H Gross; G B Toews; T V Colby; W D Travis; J A Mumford; S Murray; A Flint; J P Lynch; F J Martinez
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

9.  Inter-observer variation between pathologists in diffuse parenchymal lung disease.

Authors:  A G Nicholson; B J Addis; H Bharucha; C A Clelland; B Corrin; A R Gibbs; P S Hasleton; K M Kerr; N B N Ibrahim; S Stewart; W A H Wallace; A U Wells
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

10.  HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation.

Authors:  Z A Aziz; A U Wells; D M Hansell; G A Bain; S J Copley; S R Desai; S M Ellis; F V Gleeson; S Grubnic; A G Nicholson; S P G Padley; K S Pointon; J H Reynolds; R J H Robertson; M B Rubens
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.